Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083687 | 0.83 | ACHE (0.61) | CYP2A13CXCR4ALDH1A1KDM4EPOLB | |
| SCHEMBL19075616 | 0.82 | CYP2A13 (0.54) | CYP2A13CXCR4ALDH1A1KDM4EPOLB | |
| SCHEMBL8237166 | 0.80 | CXCR4 (0.56) | CYP2A13CXCR4ALDH1A1KDM4EPOLB | |
| SCHEMBL6944902 | 0.79 | CYP2A13 (0.59) | CYP2A13CXCR4ALDH1A1KDM4EPOLB | |
| SCHEMBL13202837 | 0.79 | CYP2A13 (0.54) | CYP2A13CXCR4ALDH1A1KDM4EPOLB | |
| SCHEMBL2445773 | 0.78 | CXCR4 (0.54) | CYP2A13CXCR4ALDH1A1KDM4EPOLB | |
| SCHEMBL3167825 | 0.78 | CXCR4 (0.59) | CYP2A13CXCR4ALDH1A1KDM4ETDP1 | |
| SCHEMBL2735346 | 0.77 | CCR3 (0.71) | CXCR4ALDH1A1KDM4EATMSIGMAR1 | |
| SCHEMBL15338728 | 0.77 | CXCR4 (0.53) | CYP2A13CXCR4ALDH1A1KDM4EPOLB | |
| SCHEMBL12401142 | 0.77 | CXCR4 (0.53) | CYP2A13CXCR4ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP2A13 661/4885CXCR4 71/4885ALDH1A1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.